Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2

Conditions

Neuroendocrine Tumors 32Multiple Endocrine Neoplasia Type 1 9Neoplasms 8Pituitary Neoplasms 7Carcinoid Tumor 7Pituitary ACTH Hypersecretion 6Gastro-enteropancreatic neuroendocrine tumor 6Differentiated Thyroid Cancer 6Adrenocortical Carcinoma 6Thyroid Cancer, Papillary 5Pituitary Diseases 5Pheochromocytoma 5Thyroid Neoplasms 4Serotonin Syndrome 4Neuroblastoma 4Cushing Syndrome 4Breast Neoplasms 4Acromegaly 4ACTH Syndrome, Ectopic 4Sarcoma 3Liposarcoma 3Insulinoma 3Fibrosarcoma 3Endometrial Neoplasms 3Carcinoma, Medullary 3Adenoma, Islet Cell 3Adenocarcinoma, Follicular 3Sarcoma, Synovial 2Sarcoma, Endometrial Stromal 2Parkinson Disease 2

Interventions

Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Octreotide 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Malignant Carcinoid Syndrome × Endocrine × Clear all
NCT00092287 2020-04-30

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

Ipsen

Phase 3 Terminated
4 enrolled
Endocrine

Malignant Carcinoid Syndrome, Serotonin Syndrome

NCT00412061 2014-11-21

RADIANT-2

Novartis

Phase 3 Completed
429 enrolled 13 charts
Endocrine

Carcinoid Tumor, Carcinoma, Malignant Carcinoid Syndrome, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡